# BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

> **NCT03527264** · PHASE2 · TERMINATED · sponsor: **Brown University** · enrollment: 4 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Nivolumab induction
- **DRUG:** Cisplatin
- **RADIATION:** Radiation
- **DRUG:** Nivolumab with chemoradiation
- **DRUG:** Nivolumab maintenance

## Key facts

- **NCT ID:** NCT03527264
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-08
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03527264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03527264, "BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03527264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*